CAMBRIDGE, Mass. | July 9, 2026
MetaVia Inc., a clinical-stage biotechnology company focused on developing innovative therapies for cardiometabolic diseases, has announced the successful completion of dose titration for all active patients enrolled in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity. The milestone marks significant progress in the development of the company’s investigational dual GLP-1/glucagon receptor agonist, with patients in both study cohorts successfully reaching the highest planned target doses of 48 mg and 64 mg. The achievement reinforces the favorable tolerability profile observed throughout the study while keeping the program on schedule to deliver topline clinical data in the fourth quarter of 2026. The advancement strengthens MetaVia’s position in the highly competitive obesity therapeutics market, where next-generation metabolic therapies are increasingly focused on delivering greater weight loss, improved metabolic outcomes, and better long-term tolerability compared with currently available treatments.
Phase 1 Trial Reaches Important Clinical Development Milestone
The ongoing Phase 1 Part 3 clinical trial is evaluating DA-1726, a novel oxyntomodulin (OXM) analogue designed to activate both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), creating a dual mechanism intended to reduce appetite while simultaneously increasing energy expenditure. The study includes approximately 40 adults with obesity, randomized across two dose-escalation cohorts to evaluate optimized titration strategies capable of safely reaching higher therapeutic doses. In Part 3A, participants progressed from 16 mg to 48 mg, while Part 3B evaluated a two-step escalation from 16 mg to 32 mg and ultimately 64 mg.
Primary study objectives include evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, treatment-emergent adverse events, and serious adverse events, while secondary endpoints assess changes in body weight, waist circumference, body mass index (BMI), glucose metabolism, lipid profiles, and other cardiometabolic biomarkers. The successful completion of dose escalation across both cohorts demonstrates that all active participants tolerated the planned dosing strategy, supporting continued clinical development.
DA-1726 Demonstrates Strong Potential in the Competitive Obesity Market
Advertisement
MetaVia continues to position DA-1726 as a differentiated next-generation obesity therapy through its dual GLP-1/glucagon receptor mechanism, which seeks to improve weight reduction by combining appetite suppression with enhanced energy expenditure. Previously reported data from the company’s Phase 1 Multiple Ascending Dose (MAD) study demonstrated encouraging clinical outcomes, including mean weight loss of 9.1% after only eight weeks of treatment at the 48 mg dose, accompanied by meaningful reductions in waist circumference, improvements in glycemic control, and early indicators of potential liver health benefits.
The company believes its efficient dose-escalation strategy could offer an important competitive advantage compared with currently marketed obesity therapies by enabling patients to safely achieve higher therapeutic doses with favorable tolerability. These encouraging findings further support the ongoing development of DA-1726 as a potential treatment for both obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), expanding its potential clinical utility across multiple cardiometabolic disorders.
MetaVia Expands Cardiometabolic Innovation Pipeline
The latest development milestone reinforces MetaVia’s commitment to advancing innovative therapies targeting obesity and metabolic disease, two of the fastest-growing therapeutic areas worldwide. In addition to DA-1726, the company is developing vanoglipel (DA-1241), a potential first-in-class GPR119 agonist for the treatment of MASH, further strengthening its cardiometabolic pipeline. By focusing on novel mechanisms that simultaneously address weight management, glucose regulation, lipid metabolism, and liver health, MetaVia aims to deliver differentiated therapies capable of addressing the complex biological drivers of chronic metabolic diseases.
With topline Phase 1 Part 3 results expected in the fourth quarter of 2026, investors, clinicians, and industry stakeholders will closely monitor whether DA-1726 continues to demonstrate the promising efficacy, tolerability, and metabolic benefits observed in earlier studies. The successful completion of dose titration represents another important step toward advancing a next-generation obesity therapy that has the potential to improve long-term patient outcomes while expanding treatment options in one of the pharmaceutical industry’s most rapidly evolving markets.
Source: MetaVia press release
